Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alvotech Warrant (ALVOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ALVOW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -0.17% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.19 | 52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 |
52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.42% | Operating Margin (TTM) 7.97% |
Management Effectiveness
Return on Assets (TTM) 7.02% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 100126591 |
Shares Outstanding - | Shares Floating 100126591 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Alvotech Warrant
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on developing and manufacturing biosimilar versions of major biologic drugs. The warrant likely relates to Alvotech's business combination with Oaktree Acquisition Corp. II, completed in 2022, resulting in Alvotech becoming a publicly listed company.
Core Business Areas
- Biosimilar Development and Manufacturing: Alvotech focuses on creating biosimilars for complex biologics used in the treatment of various diseases, including autoimmune disorders, oncology, and inflammatory conditions. Their core competency is in the development, manufacturing, and commercialization of these biosimilars.
Leadership and Structure
Alvotech is led by Robert Wessman (Founder and Chairman) and is a global organization with headquarters in Iceland.
Top Products and Market Share
Key Offerings
- AVT02 (Biosimilar Adalimumab): This is Alvotech's biosimilar version of AbbVie's Humira (adalimumab). Humira is a blockbuster drug used to treat autoimmune diseases. Market share data is currently developing, but competition includes biosimilars from Amgen (AMGN), Sandoz (SDZ), and other biosimilar manufacturers.
- AVT04 (Biosimilar Ustekinumab): Alvotech's biosimilar version of Janssen's Stelara (ustekinumab). Stelara is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Competition includes biosimilars from other companies once patents expire.
Market Dynamics
Industry Overview
The biosimilars market is a growing segment of the pharmaceutical industry, driven by the expiration of patents on originator biologics and the increasing need for cost-effective treatment options.
Positioning
Alvotech positions itself as a key player in the biosimilars market, focusing on developing high-quality, affordable alternatives to originator biologics. Their competitive advantage lies in their expertise in biosimilar development and manufacturing.
Total Addressable Market (TAM)
The global biosimilars market is projected to reach hundreds of billions of USD by 2030. Alvotech is positioned to capture a significant portion of this TAM by developing biosimilars for blockbuster biologics.
Upturn SWOT Analysis
Strengths
- Strong pipeline of biosimilar candidates
- Expertise in biosimilar development and manufacturing
- Global reach
- Strategic partnerships
Weaknesses
- Limited commercialized products
- Reliance on regulatory approvals
- Intense competition in the biosimilars market
- Patent litigation risks
Opportunities
- Increasing demand for biosimilars
- Expansion into new markets
- Strategic collaborations and acquisitions
- Advancements in biosimilar technology
Threats
- Delays in regulatory approvals
- Patent challenges and litigation
- Pricing pressures from competitors
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- AMGN
- SDZ
- VTRS
- PFE
- MRK
Competitive Landscape
Alvotech faces intense competition in the biosimilars market from established pharmaceutical companies and other biosimilar developers. Alvotech differentiates itself through its focus on high-quality, affordable biosimilars and its strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Growth of the warrant is tied to the performance of ALVO. As Alvotech launches more Biosimilars and increases profit, the value of the Warrant increases
Future Projections: Future projections for the warrant depend on analyst estimates for Alvotech's stock price, which are tied to the success of its biosimilar pipeline.
Recent Initiatives: Recent strategic initiatives include the commercialization of AVT02 (biosimilar adalimumab) in various markets and the advancement of other biosimilar candidates in its pipeline.
Summary
Alvotech is a biosimilar company with a strong pipeline of products targeting blockbuster biologics. While the warrant offers potential upside from the company's growth, it also carries significant risk due to regulatory hurdles and intense competition. The company's success hinges on the successful development and commercialization of its biosimilar candidates and effective management of intellectual property risks. Investors should carefully consider the risks and potential rewards before investing in Alvotech's warrant.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.